Abstract
DMD is a devastatingly progressive muscle wasting disorder of childhood that significantly shortens life expectancy.Despite efforts to develop an effective therapy that dates back over a century, clinical interventions are still restrictedto management of symptoms rather than a cure. The rationale to develop effective therapies changed in 1986 withthe discovery of the dystrophin gene. Since then extensive research into both the molecular basis and pathophysiology ofDMD has paved the way not only for development of strategies which aim to correct the primary defect, but also towardsthe identification of countless therapeutic targets with the potential to alleviate the downstream pathology. In addition togene and cell-based therapies, which aim to deliver the missing gene and/or protein, an exciting spectrum of pharmacologicalapproaches aimed at modulating therapeutic targets within DMD muscle cells through the use of small drugs arealso being developed. This review presents promising pharmacological approaches aimed at targeting the primary defect,including suppression of nonsense mutations and functional compensation by upregulation of the dystrophin homologue,utrophin. Downstream of the primary membrane fragility, inflammation and fibrosis are reduced by blocking NF-κB,TGF-α and TGF-β, and free radical damage has been targeted using antioxidants and dietary/nutritional supplements.There are new hopes that ACE and PDE5 inhibitors can protect against skeletal as well as cardiac pathology, and modulatingCa2+ influx, NO, BMP, protein degradation and the mitochondrial permeability pore hold further promise in tacklingthe complex pathogenesis of this multifaceted disorder.
Keywords:Cardiac, duchenne, dystrophy, fibrosis, inflammation, muscular, pharmacological, utrophin, DMD, mdx
Current Gene Therapy
Title:Pharmacologically Targeting the Primary Defect and Downstream Pathology in Duchenne Muscular Dystrophy
Volume: 12Issue: 3
Author(s):Rebecca J. Fairclough, Kelly J. Perkins and Kay E. Davies
Affiliation:
Keywords:Cardiac, duchenne, dystrophy, fibrosis, inflammation, muscular, pharmacological, utrophin, DMD, mdx
Abstract: DMD is a devastatingly progressive muscle wasting disorder of childhood that significantly shortens life expectancy.Despite efforts to develop an effective therapy that dates back over a century, clinical interventions are still restrictedto management of symptoms rather than a cure. The rationale to develop effective therapies changed in 1986 withthe discovery of the dystrophin gene. Since then extensive research into both the molecular basis and pathophysiology ofDMD has paved the way not only for development of strategies which aim to correct the primary defect, but also towardsthe identification of countless therapeutic targets with the potential to alleviate the downstream pathology. In addition togene and cell-based therapies, which aim to deliver the missing gene and/or protein, an exciting spectrum of pharmacologicalapproaches aimed at modulating therapeutic targets within DMD muscle cells through the use of small drugs arealso being developed. This review presents promising pharmacological approaches aimed at targeting the primary defect,including suppression of nonsense mutations and functional compensation by upregulation of the dystrophin homologue,utrophin. Downstream of the primary membrane fragility, inflammation and fibrosis are reduced by blocking NF-κB,TGF-α and TGF-β, and free radical damage has been targeted using antioxidants and dietary/nutritional supplements.There are new hopes that ACE and PDE5 inhibitors can protect against skeletal as well as cardiac pathology, and modulatingCa2+ influx, NO, BMP, protein degradation and the mitochondrial permeability pore hold further promise in tacklingthe complex pathogenesis of this multifaceted disorder.
Export Options
About this article
Cite this article as:
J. Fairclough Rebecca, J. Perkins Kelly and E. Davies Kay, Pharmacologically Targeting the Primary Defect and Downstream Pathology in Duchenne Muscular Dystrophy, Current Gene Therapy 2012; 12 (3) .https://dx.doi.org/10.2174/156652312800840595
| DOI https://dx.doi.org/10.2174/156652312800840595 | Print ISSN 1566-5232 |
| Publisher Name Bentham Science Publisher | Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Advances in CAR-T Cell Therapy and CRISP combination
CAR-T cell therapy is a groundbreaking immunotherapy that has transformed cancer treatment, particularly in hematological malignancies like leukemia and lymphoma. It involves engineering a patient’s own T cells to express chimeric antigen receptors (CARs) that target and destroy cancer cells. The therapy has demonstrated remarkable success, achieving durable remissions in ...read more
Melatonin Signaling in Health and Disease
Melatonin regulates a multitude of physiological functions, including circadian rhythms, acting as a scavenger of free radicals, an anti-inflammatory agent, a modulator of mitochondrial homeostasis, an antioxidant, and an enhancer of nitric oxide bioavailability. AANAT is the rate-limiting enzyme responsible for converting serotonin to NAS, which is further converted to ...read more
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers.
Programmed cell death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
The now and future of gene transfer technologies
Gene and cell therapies rely on a gene delivery system which is safe and effective. Both viral and non-viral vector systems are available with specific pros and cons. The choice of a vector system is largely dependent on the application which is a balance between target tissue/disease and safety, efficacy ...read more
Related Journals
Related Books
Plant-Microbe Interactions: A Comprehensive Review
Glycosylation and Glycation in Health and Diseases
Phytogenic and Phytochemical as Alternative Feed Additives for Animal Production
Methods and Techniques in Nematology
Mind Maps in Clinical Biochemistry
A Treatise on Ecological Science
From SARS-CoV to MARS-CoV
Microbiology for ICAR NET: A Comprehensive Exam Preparation Guide
Decolorization by Thanatephorus Cucumeris Dec 1
Industrial Applications of Soil Microbes
62
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
- PREFACE: Cardiovascular and Hematological Medicine in 2015 - Advances and Insights
Cardiovascular & Hematological Agents in Medicinal Chemistry Erythropoietin and Wnt1 Govern Pathways of mTOR, Apaf-1, and XIAP in Inflammatory Microglia
Current Neurovascular Research Gene Therapy Strategies to Prevent Autoimmune Disorders
Current Gene TherapyPathophysiology, Diagnosis and Clinical Management of Hepatorenal Syndrome: From Classic to New Drugs
Current Vascular Pharmacology Pharmacological Therapy in Children with Atrial Fibrillation and Atrial Flutter
Current Pharmaceutical DesignPrognostic Role of miRNAs in Coronary Artery Disease
Current Topics in Medicinal ChemistryClinical Review of COVID-19; Pathogenesis, Diagnosis, and Management
Current Pharmaceutical Design Cyclosporin and Organ Specific Toxicity: Clinical Aspects, Pharmacogenetics and Perspectives
Current Clinical PharmacologyCardioprotective Role of <i>Tinospora cordifolia</i> against Trimethylamine-N-Oxide and Glucose Induced Stress in Rat Cardiomyocytes
Cardiovascular & Hematological Agents in Medicinal ChemistryThe Chemical Design and Synthesis of Linkers Used in Antibody Drug Conjugates
Current Topics in Medicinal ChemistryCellular and Mitochondrial Pathways Contribute to SGLT2Inhibitors-mediated Tissue Protection: Experimental and Clinical Data
Current Pharmaceutical DesignMedical Treatment of Aortic Aneurysms in Marfan Syndrome and other Heritable Conditions
Current Cardiology Reviews The Zebrafish as a Novel Tool for Cardiovascular Drug Discovery
Recent Patents on Cardiovascular Drug Discovery Molecular Basis of Antiretroviral Drugs-Associated Long-Term Toxicity: How Bad can Good Drugs Be?
Current Medicinal Chemistry - Anti-Infective AgentsHost Innate Immune Responses to Microbial Pathogens
Current Vascular PharmacologyAntioxidant Mechanisms in Nonalcoholic Fatty Liver Disease
Current Drug TargetsParkinson’s Disease: Is there a Role for Dietary and Herbal Supplements?
CNS & Neurological Disorders - Drug TargetsThe Concept of Titration can be Transposed to Fluid Management. But does is Change the Volumes? Randomised Trial on Pleth Variability Index During Fast-Track Colonic Surgery
Current Clinical PharmacologyAcute Cardioembolic Cerebral Infarction: Answers to Clinical Questions
Current Cardiology Reviews The Emerging Role of Vascular Endothelial Growth Factor (VEGF) in Vascular Homeostasis: Lessons from Recent Trials with Anti-VEGF Drugs
Current Vascular Pharmacology
[8]ページ先頭